Table 1.

Novel Pim-Inhibitors in hematologic malignancies

Compound	Class	PIM inhibition selectivity	Development	Disease
SGI-1776	imadizaopyridazine	IC50: 7 nM PIM1, 363 nM PIM2, 69 nM PIM3, 44 nM FLT-3 and 34 nM Haspin [107].	Failure in phase I clinical trials by cardiotoxicity	Non-Hodgkin lymphoma
SMI4a	benzylidene-thiazolidene-2,4-dione	IC50: 21 nM PIM1, 100 nM PIM2 [113].	Preclinical	Acute myeloid leukemia
		Selective vs. 56 kinases [114].
LGB321	3-(S)-amino-piperidine pyridyl carboxamide	IC50: 0.001 nM PIM1, 0.0021 nM PIM2, and 0.0008 nM PIM3 [106].	Recruiting patients for clinical trials	Multiple myeloma
AZD1897		IC50: 3 nM PIM1,2 and 3 [115].	Preclinical	Acute myeloid leukemia
SEL24-B58	Benzoimidazol	IC50: 31 nM PIM1, 154 nM PIM2, 152 nM PIM3. Selective in a panel of 299 kinases with the exception of haspin, HIPK and CLK kinases [117].	Preclinical	Leukemic monocyte lymphoma
AZD1208	thiazolidene	IC50: Pim-1 0.4 nM, Pim-2 5.0 nM and Pim-3 1.9 nM [115].	Recruiting patients for clinical trials	Acute myeloid leukemia